Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

TD Tele-Doc Weight Loss vs Wisp

TD Tele-Doc Weight Loss
Graded #288

Lower grade

vs+13.200000000000003
Wisp
Graded #59

Higher grade

The verdict

Wisp takes it — 75/100 to 61.8/100.

Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWisp +38
45
83
Dose & formulationWisp +35
53
88
Clinical oversightTD Tele-Doc Weight Loss +6
88
82
Labs & monitoringTD Tele-Doc Weight Loss +12
65
53
FulfillmentTD Tele-Doc Weight Loss +2
68
66
Contract termsEven
55
55
TD Tele-Doc Weight Loss · left barWisp · right bar

The numbers

MetricTD Tele-Doc Weight LossWisp
WeighScore61.8/10075/100
GradeCC
Scorecard rank#288#59
SemaglutideNot disclosed$225/mo (compounded oral)
TirzepatideNot disclosed$99/mo (starting dose, brand-name)
Coverage2 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
TD Tele-Doc Weight Loss

Graded #288 · C

Strengths

  • Brand Wegovy/Zepbound AND compounded sema available; prescribing based on medical history and coverage
  • 100% virtual — weekly appointments with board-certified MDs from home; no travel required
  • Remote Patient Monitoring Starter Box: biometric scale + blood pressure cuff sync to care team in real time
  • In-network with most commercial insurance plans; may cover visits and monitoring equipment
  • Physician-led by Dr. Peter Wilbanks MD (30-yr OB/GYN, VCU) and Dr. Michael Perini MD (ABIM board-certified)

Where it loses points

  • No public cash pricing; cost entirely depends on insurance coverage — not viable for uninsured patients
  • Telehealth available only in Virginia and Maryland; no national reach confirmed
  • No Medicare or Medicaid accepted; limited to commercial insurance plans only
  • No LegitScript certification found; compounded availability and specific pricing undisclosed on site
  • Tirzepatide (Zepbound/Mounjaro) availability less prominent in MD pages; semaglutide is primary focus
Wisp

Graded #59 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
  • Pharmacy partners not named
  • States served not listed publicly

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard